on 28 Apr 2020
Last Applicant/ Owned by
85748 Garching
DE
Serial Number
79265476 filed on 05th Jun 2019
Registration Number
6039395 registered on 28th Apr 2020
Correspondent Address
Kari Moyer-Henry
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Pharmaceutical advice in relation to radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, advice in relation to radiopharmaceuticals for the therapy and diagnosis of diseases, in particular tumour diseases, namely, pharmaceutical advice in relation to radiopharmaceuticals coupled to somatostatin analogues and advice in relation to the manufacture of p Read More
Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing Gallium-68 for treating and diagnosing tumours; anti-cancer preparations, namely, Gallium-68 compounds, including 68-Ga chlorides; anti-cancer preparations, namely, Gallium-68 for use in the field of targeted radionuclide therapy of cancers, in particular prostate cancer and neuroendocrine tumours; cancer diagnostic preparations for medical purposes, namely, Gallium-68 compounds, including 68-Ga peptide chelates, in particular 68-Ga-Dotatoc and 68-Ga-Dotatate, 68-Ga salts, in particular 68-Ga chlorides; Gallium-68 for use as radiotracers in pet scans or combined PET/CT scans
Medical apparatus and instruments for use in positron emission tomography (PET) imaging, namely, Ge-68/Ga-68 radionuclide generators for pharmaceutical purposes as source of radionuclides being positron emitters in the field of Positron Emission Tomography - Computed Tomography (PET/CT)
Scientific and technological services and research on radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, services relating to radiopharmaceuticals for the therapy and diagnosis of diseases and services relating to radiopharmaceuticals coupled to somatostatin analogues for the diagnosis and treatment of tumours, namely, scientific and product research and development
Pharmaceutical advice in relation to radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, advice in relation to radiopharmaceuticals for the therapy and diagnosis of diseases, in particular tumour diseases, namely, pharmaceutical advice in relation to radiopharmaceuticals coupled to somatostatin analogues and advice in relation to the manufacture of personalised radiopharmaceutical products containing 68-Ga for use in medicine
No 79265476
No Service Mark
No 540.318US
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
26th Sep 2020 | FINAL DECISION TRANSACTION PROCESSED BY IB |
08th Sep 2020 | FINAL DISPOSITION NOTICE SENT TO IB |
04th Sep 2020 | FINAL DISPOSITION PROCESSED |
28th Jul 2020 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
03rd Jul 2020 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
28th Apr 2020 | REGISTERED-PRINCIPAL REGISTER |
14th Feb 2020 | NOTIFICATION PROCESSED BY IB |
11th Feb 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
11th Feb 2020 | PUBLISHED FOR OPPOSITION |
29th Jan 2020 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |